SPOTLIGHT: Prometheus is IPO bound

Prometheus Laboratories, which is making a name for itself in the arena of diagnostic tests and personalized medicine, has filed for an IPO designed to raise up to $100 million. Prometheus specializes in treating gastrointestinal disorders, integrating drugs and diagnostics. The company's revenue rose to $165 million in the first nine months of this year, with earnings down for the same period. Report